Ernest Marshall

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 389 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.

M. Hussain, Michael Wolf, Ernest Marshall et al. · Journal of Clinical Oncology · 1994 · 164 citations

Medicine, Oncology, Urology +17

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial

Serge Leyvraz, Sophie Piperno‐Neumann, Stefan Suciu et al. · Annals of Oncology · 2014 · 147 citations · Full text

Medicine, Oncology, Surgery +17

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study

Pippa Corrie, Andrea Marshall, Janet Dunn et al. · The Lancet Oncology · 2014 · 109 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice

Helen Innes, Sheow Lei Lim, Allison Hall et al. · Supportive Care in Cancer · 2007 · 84 citations

Medicine, Oncology, Chemotherapy +14